Targus

Quick links to important sections

Targus

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Targus

Quick Facts

Property Description
Active ingredient Flurbiprofen
Form Oral Tablet (typically film-coated)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic/Derived (Propionic Acid derivative)

What is Targus?

What Type of Medicine is Targus?

Targus is a single-ingredient pharmaceutical preparation, typically delivered as an Oral Tablet, whose active compound is Flurbiprofen. Flurbiprofen is chemically classified as a Propionic Acid derivative, which firmly places the medicine within the family of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification establishes the product's nature as a synthetic agent intended for systemic use following its administration by the oral route. The use of Flurbiprofen for reducing physical discomfort is clinically recognized, supporting its therapeutic placement as an NSAID.

Flurbiprofen: The Compound and Its General Purpose

The fundamental purpose of Targus is to provide symptomatic relief from physical discomfort by simultaneously addressing the core signs of inflammation, pain, and fever. This comprehensive action is accomplished because Flurbiprofen functions by inhibiting the synthesis of prostaglandins, which are key biochemical messengers that heighten pain sensations and are central to the body's inflammatory response.

The effectiveness of Flurbiprofen in this regard is recognized; the compound exhibits anti-inflammatory effects alongside its pain-relieving properties, providing a dual benefit. As a result of this mechanism, the core therapeutic benefits are its established anti-inflammatory activity, which reduces swelling and stiffness; its analgesic activity, which lessens pain signals; and its antipyretic activity, which aids in the reduction of fever. Targus is positioned as a medicine used to provide relief from symptoms associated with conditions such as chronic arthritis or acute soft tissue inflammation, offering a comprehensive means of restoring general patient comfort.

Regulatory References

  1. NIH LiverTox Flurbiprofen
  2. MedlinePlus Flurbiprofen Information

What side effects are possible with Targus?

Possible side effects and safety information

The safety profile of Targus (Flurbiprofen) is officially documented by government regulatory bodies, classifying adverse reactions by frequency and the organ system affected. The most frequently observed, or common, reactions are typically gastrointestinal and nervous system effects. These commonly listed effects include dyspepsia (indigestion), nausea, abdominal pain, headache, and dizziness.


Official Regulatory Safety Constraints

Flurbiprofen, like other nonsteroidal anti-inflammatory drugs (NSAIDs), carries mandated warnings regarding the potential for serious adverse reactions. These severe risks involve specific organ systems, as documented by regulatory authorities:

  • Serious Gastrointestinal Events: Official labeling documents the risk of severe, potentially fatal events, including ulceration, bleeding, and perforation of the stomach or intestines. These can occur at any time during treatment.
  • Serious Cardiovascular Thrombotic Events: Targus is associated with the risk of serious, potentially fatal cardiovascular thrombotic events, such as myocardial infarction (MI) and stroke. This risk may occur early in treatment and is officially documented to increase with the duration of use.

Population and Contextual Safety Notes

The prescribing information includes specific safety constraints for certain populations and clinical settings:

Safety Note Description (Official Regulatory Statement)
Late Pregnancy Use is officially mandated to be avoided starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus.
Older Adults This population is recognized in labeling as being at a greater risk for serious gastrointestinal adverse events.
Contraindication The medicine is strictly contraindicated for the treatment of pain immediately following Coronary Artery Bypass Graft (CABG) surgery.

Serious hypersensitivity reactions, including anaphylaxis and severe skin reactions (Stevens-Johnson syndrome), are also officially documented but are classified in the rare to very rare frequency tiers.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Targus (Flurbiprofen) is officially documented by regulatory authorities to involve systemic toxicity, primarily affecting the central nervous and gastrointestinal systems.

Documented Manifestations Potential Severe Outcomes
Somnolence, Confusion, Convulsions Coma
Abdominal pain, Nausea, Vomiting Acute Renal Failure
Shallow breathing, Cyanosis Severe GI Bleeding or Perforation

The clinical presentation in overdose situations commonly includes CNS signs such as lethargy, unusual drowsiness, or confusion, which may progress to convulsions or loss of consciousness. Gastrointestinal manifestations like severe upper stomach pain and vomiting are also highly documented. Due to Flurbiprofen's classification as an NSAID, severe or life-threatening outcomes can include acute renal failure, metabolic acidosis, and major gastrointestinal bleeding or perforation.

Mandatory Emergency Action

Immediate medical attention is required for any suspected overdose. Regulator guidance explicitly states that emergency services must be called immediately if the person collapses, is experiencing a seizure, has trouble breathing, or cannot be awakened. No specific antidote is known for Flurbiprofen overdose. Official management is symptomatic and supportive, focusing on maintaining vital functions. Elderly patients are noted in official labeling as being at increased risk for severe gastrointestinal and renal adverse events in overdose situations.

Therapeutic Uses of Targus

What Targus Treats: Main Uses and Benefits

Targus (Flurbiprofen) is generally considered relevant in contexts involving inflammatory or irritative states where supportive symptom management is appropriate. The medication is used for managing symptoms that interfere with daily comfort.

Targus may assist with managing the overall symptom burden across conditions presenting with acute or chronic episodes. It is commonly used to help with symptomatic relief in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and the pain associated with dysmenorrhoea. This supportive benefit helps address symptom clusters that may become intense or disruptive, and may assist with maintaining functional stability.

“It is used across domains where additional symptomatic support is needed in contexts involving increased discomfort or tension.”

It is often used when symptoms intensify and supportive relief is needed, particularly for pain, swelling, stiffness, and fever.

Quick Fact: Relief for Key Symptoms
Primary Actions Analgesic, Anti-inflammatory, Antipyretic
Target Symptoms Pain, Swelling, Stiffness, Fever
Patient Benefit Contributes to improved comfort during symptomatic periods and helps ease symptom load

Regulatory References

  1. Flurbiprofen: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Targus (Flurbiprofen)

The eligibility for Targus, an NSAID containing Flurbiprofen, is strictly defined by regulatory documents based on a patient's age and pre-existing health status. Use is generally established for extbfadults (mathbf18 extbfyears and older) who are free from specific contraindications.


Absolute Contraindications

Flurbiprofen extbfmust not be used by the following populations:

  • Patients with extbfsevere heart, extbfhepatic, or extbfrenal failure.
  • Individuals with a history of extbfallergic-type reactions (e.g., asthma, urticaria) to extbfaspirin or other NSAIDs.
  • During the extbfthird trimester of pregnancy (from 30 weeks gestation).
  • For extbfperi-operative pain in the setting of extbfCoronary Artery Bypass Graft (CABG) surgery.
  • Those with extbfactive or extbfrecurrent peptic ulcers or extbfgastrointestinal hemorrhage.

Populations Requiring Caution or Restriction

The medicine is extbfnot recommended for the extbfpediatric population (typically under 12 years) as safety and efficacy have extbfnot been established. extbfOlder adults (mathbf65 extbfyears and older) must use Flurbiprofen with extbfcaution due to increased risk of complications. Use is extbfrestricted for those with extbfmild to moderate renal or hepatic impairment and is extbfnot recommended during extbfbreastfeeding. Use during the extbffirst and second trimesters of pregnancy should be extbfavoided unless specifically directed.

What should I know about interactions with other medicines?

The regulatory documentation for Targus (Flurbiprofen) outlines specific interaction patterns classified across pharmacokinetic and pharmacodynamic domains.

Officially, co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is restricted due to the combined risk of serious gastrointestinal adverse events. Use with analgesic doses of Aspirin is not generally recommended, although low-dose Aspirin may be permitted under medical guidance.

Pharmacodynamic Effects: Targus exhibits a synergistic effect on hemostasis, officially increasing the risk of serious bleeding when combined with Anticoagulants (such as Warfarin), Antiplatelet agents, SSRIs/SNRIs, or Alcohol. Flurbiprofen may also officially diminish the therapeutic effect of certain blood pressure medicines, including ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics. This combination carries a documented risk of renal function deterioration in vulnerable populations, such as elderly or volume-depleted patients.

Pharmacokinetic Effects: The medicine is primarily metabolized by the CYP2C9 enzyme. Inhibitors of this enzyme, such as Fluconazole, can officially reduce Flurbiprofen clearance and increase its plasma exposure. Furthermore, co-administration decreases the renal clearance of Lithium, which can lead to increased serum Lithium concentrations. Caution is also documented for co-administration with Methotrexate, particularly when administered within 24 hours, due to the official risk of increased toxicity. Food or antacids may alter the rate but not the extent of Flurbiprofen absorption.

Mechanism of Action

How Targus Works

The active compound in Targus, Flurbiprofen, functions by directly intervening in the body's eicosanoid signaling pathway. Its mechanism is defined by a non-selective interaction with two key enzymes, initiating a three-part physiological cascade.

Molecular Mechanism: Non-Selective Enzyme Inhibition

Flurbiprofen acts as a reversible competitive inhibitor of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular intervention blocks the ability of the enzymes to convert the precursor substance, arachidonic acid, into prostaglandins—the inflammatory chemical mediators. This mechanism immediately modulates the upstream source of these signaling molecules.

Physiological Cascade: Dampening Systemic Responses

This reduction in prostaglandin synthesis leads to a three-part change in physiological function. Primarily, it desensitizes peripheral nociceptive neurons, reducing nociceptive signaling input. Secondly, it decreases the local production of pro-inflammatory mediators, which modulates the mediators that influence local vascular permeability. Finally, by reducing PGE2 specifically in the hypothalamus, the drug influences the hypothalamic thermal set-point regulation and modulates the pyretic response.

Mechanism Constraint: Dual Target Consequence

A necessary consequence of this non-selective mechanism is the co-inhibition of COX-1, which performs constitutive functions, such as regulating gastric mucosal integrity. This functional constraint highlights an intrinsic limitation: its action on inflammatory pathways is linked to its influence on other necessary physiological processes.

Dosage and Administration Information

Administration and Dosing of Targus

Targus (Flurbiprofen) is strictly administered via the oral route as a tablet. The protocol for use defines precise dosing, frequency, and administration conditions. The intent of use is to administer the lowest effective dose for the shortest duration necessary, in accordance with established protocols.


Official Dosing Regimen

Feature Guideline
Route of Administration Oral
Total Daily Dose Range 200 mg to 300 mg per day for chronic conditions.
Maximum Daily Dose Must not exceed 300 mg.
Frequency Pattern Administered in divided doses (2, 3, or 4 times daily).

Procedural Conditions for Intake

Administration must adhere to specific procedural rules. The tablet should be taken with food, milk, or a full glass of water (8 to 12 oz) to support proper physical tolerance and absorption. It is a mandatory condition that the tablet must be swallowed whole and is not to be crushed, broken, or chewed.

Administration over time is structured around using the lowest effective dosage for the shortest possible duration. Dosage modifications may be necessary for older adults, and the medication is generally not recommended for patients with advanced liver or kidney impairment.

Recent Clinical Evidence

Research Evidence for Targus (Flurbiprofen) Studies Overview


Evidence for Chronic Inflammatory Joint Conditions

The primary research base for oral Targus (Flurbiprofen) research examined the symptomatic response in individuals diagnosed with chronic conditions like rheumatoid arthritis and osteoarthritis. The initial evidence relies on Randomized Controlled Trials (RCTs) and systematic reviews. Research in this area examined outcomes related to physical discomfort, such as the perceived intensity of joint pain and stiffness, and also monitored patient-reported outcomes describing perceived discomfort and activity level.

Trials documented that treatment was associated with measurements of changes in reported discomfort and stiffness compared to control groups. The evidence contributes to the available research on symptomatic patterns in the context of conditions involving functional limitations. The findings are based on the populations studied; individuals with severe underlying health issues were often excluded from these studies.


Evidence for Acute Musculoskeletal Pain and Inflammation

Research exploring short-term symptom changes was applied in studies examining patient-reported experiences of acute or intense pain, such as that associated with tendinitis, bursitis, or post-operative discomfort. These short-term RCTs examined outcomes describing episodic or acute changes in pain intensity over defined intervals, such as a few hours or a few days. Research focused on episodes where symptoms were reported as increased.

Studies monitored responses and focused on examining the measurement differences in reported acute discomfort compared to placebo. This evidence provides insight related to short-term changes but not the resolution of the underlying condition. The certainty remains low for the long-term effects beyond the typical follow-up durations of the primary RCTs, meaning the full scope of use and the long-term changes in functional outcomes over decades are not fully established.

Key Studies & References

  1. Label: FLURBIPROFEN tablet, film coated (DailyMed/NIH)

Frequently Asked Questions (FAQ)

Common questions about Targus (FAQ)

Q: Is Targus the same type of medicine as [similar common drug name]?

A: Official regulatory documents classify Targus (Flurbiprofen) as a Propionic Acid derivative and a type of Nonsteroidal Anti-inflammatory Drug (NSAID). This places it within the same general drug class as other common pain-relieving and anti-inflammatory medicines. Its specific chemical classification determines its therapeutic effects.

Q: Is it true that Targus is considered a long-term treatment?

A: Official guidance emphasizes that use should be limited to the lowest effective dosage for the shortest duration possible. This recommendation minimizes potential risks associated with prolonged use. Official guidance emphasizes that use should be limited to the shortest duration possible, aligning it away from typical long-term use.

Q: Do food or beverages need to be avoided when using Targus?

A: Official information advises discussing with a healthcare professional the use of alcohol or tobacco while taking this medicine. This is because these substances may increase the risk of serious gastrointestinal adverse events. For safety, it is important that all lifestyle factors and substances are disclosed to a healthcare provider.

Q: Is Targus approved for use in older adults?

A: While the medicine is sometimes prescribed to older adults, regulatory warnings indicate that this population is at a greater risk for serious complications, including problems with the digestive system, kidneys, and heart. This increased risk means healthcare professionals must use caution when prescribing it to this population.

Q: Why are there warnings about liver function associated with Targus?

A: Targus is associated with a reported risk of liver damage, a condition known as hepatotoxicity. Official guidance advises patients to monitor for and report signs of liver issues, such as yellowing of the skin (jaundice) or abdominal pain. The warning exists because severe hepatic failure is recognized as a strict contraindication for its use.

Q: Does Targus have a Black Box Warning in the official FDA documents?

A: Yes, the official FDA label for Flurbiprofen includes a Boxed Warning, which is sometimes referred to as a Black Box Warning. This is the most serious warning required by the FDA. It highlights the risks of serious cardiovascular events (like heart attack or stroke) and severe gastrointestinal events (like bleeding or perforation).

Q: Can Targus cause issues with driving or operating machinery?

A: Regulatory documentation lists possible nervous system side effects such as dizziness, drowsiness, and confusion. Because these effects may impair concentration and coordination, official documents recommend caution regarding activities that require full mental alertness, such as driving or operating machinery.

Q: Are there any known issues combining Targus with over-the-counter cold medicines?

A: Regulatory information specifically warns against using Targus with other NSAIDs because the combination greatly increases the risk of side effects. Since many over-the-counter cold medicines contain other NSAIDs (like ibuprofen), this combination is a matter for consultation with a healthcare professional.

Q: Does taking Targus change how I should monitor my health?

A: Due to the medicine's potential to affect key organ systems, official warnings advise that healthcare providers may need to monitor certain health indicators. This may include monitoring blood pressure, kidney function, and blood cell counts throughout the course of treatment. Official documents state that patients should be alert to and report signs of fluid retention or gastrointestinal bleeding.

Q: Does Targus require any special kind of diet?

A: Official prescribing information requires that Targus be taken with food, milk, or a full glass of water. This procedural condition is intended to support physical tolerance and absorption, particularly concerning the digestive system.

Q: What is the expected long-term benefit of using Targus?

A: Flurbiprofen is approved for the purpose of relieving pain, inflammation, and stiffness associated with chronic conditions. Official documents suggest that the symptomatic relief provided by the medicine continues only while the patient is taking it.

Q: Why is it important to keep track of side effects while on Targus?

A: It is important to track side effects because official regulatory warnings indicate that some serious adverse events, such as gastrointestinal bleeding or heart problems, can occur without clear initial symptoms. Prompt reporting of any new or worsening effects is necessary for safe management.

Q: Does the time of day matter when taking Targus?

A: The official dosing requirements call for the medicine to be administered in divided doses throughout the day, often two to four times daily. While the documentation focuses on the frequency, the exact clock-time of the dose (morning or night) is a detail that is determined by the prescribing healthcare professional.

Q: Is it correct that Targus needs to be taken consistently to work best?

A: According to official patient resources, when Targus is used to manage a continuing condition, it must be taken regularly as prescribed. Consistency is important to maintain the concentration of the drug at levels that provide ongoing symptomatic benefit.

Q: Why is regular follow-up with a doctor mentioned in the materials for Targus?

A: Regulatory documents emphasize the need for regular follow-up appointments because Targus carries risks of serious, potentially fatal adverse events. A healthcare provider needs to monitor symptoms and may order specific tests to assess the body's response and manage potential risks.

Q: How quickly should someone expect Targus to start working?

A: According to official patient information, the pain-relieving effects usually begin to be noticeable within one week of starting the medicine. However, the full anti-inflammatory benefits, particularly for chronic inflammatory conditions, may take two weeks or longer to be fully felt.

Q: Can Targus affect sleep patterns?

A: Official documentation confirms that Targus can affect sleep patterns, listing both insomnia (difficulty sleeping) and somnolence (drowsiness) as reported side effects. Patients who experience new or worsening sleep issues should consult with a healthcare provider.

Q: What should I know about taking Targus with vitamins or supplements?

A: Official patient resources advise that certain supplements, including herbs like ginger, garlic, or ginkgo, may interact with Flurbiprofen and potentially affect bleeding risk. All over-the-counter supplements and herbs must be disclosed to a healthcare provider for review.

Q: Is there a generic version of Targus available?

A: Yes, the active ingredient in Targus is Flurbiprofen, which is available as a generic oral tablet. The generic form of the medicine has the same active ingredients, dosage form, and strength as the brand-name product.

Q: What happens if I miss taking Targus occasionally?

A: Official regulatory instructions for a missed dose advise taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Official instructions advise not to double doses.

Q: Are there any specific activities or sports that are restricted while using Targus?

A: While official documents do not list specific restrictions on sports or activities, caution is advised for activities that require full mental alertness. This warning is based on the documented possibility of side effects like dizziness or drowsiness.

Q: Why does the packaging list so many potential drug interactions?

A: The extensive list of potential drug interactions stems from two key factors documented in regulatory texts. The medicine's mechanism involves widespread prostaglandin modulation, and it is primarily processed in the body by the CYP2C9 enzyme. This combination makes it chemically active with numerous other compounds.

Q: Is Targus known to cause weight gain or loss?

A: Official regulatory documents list body weight changes and unexplained weight gain as reported side effects associated with the medicine. Unexplained weight gain can also be a sign of fluid retention, which is another condition monitored by healthcare providers.

Q: Why do some people report feeling tired after starting Targus?

A: Tiredness is a reported side effect of Targus; official information lists fatigue/unusual tiredness, somnolence (drowsiness), and malaise (general discomfort). Additionally, the medicine may also cause or worsen anemia, which is a condition that can contribute to feelings of tiredness.

Q: What is the general duration of effect for a dose of Targus?

A: Regulatory data confirms the mean terminal disposition half-life (t1/2) is approximately 4.7 to 5.7 hours after a single dose. The half-life is a measure of the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Can Targus cause skin sensitivity to the sun?

A: Regulatory-based patient information suggests the medicine may cause increased sensitivity of the skin to sunlight, a reaction known as photosensitivity. Official patient information suggests limiting time in direct sun, avoiding tanning beds, and using protective clothing while taking this medicine.

Q: What does the term 'contraindication' mean for Targus?

A: According to official regulatory terminology, a contraindication is a specific condition or circumstance that makes the use of the medicine strictly forbidden. This means using the medicine under a listed contraindication carries a high and unacceptable risk of harm.

Q: Does official labeling describe Targus as potentially addictive?

A: No, official labeling for Targus (Flurbiprofen) does not describe it as having potential for addiction or substance abuse. It is not listed as a controlled substance by regulatory authorities.

Q: Can Targus affect birth control effectiveness?

A: Regulatory information for Flurbiprofen does not specifically list oral contraceptives as a documented drug interaction. However, because Targus may interact with many compounds, patients must always confirm the safety of all co-administered medications with a healthcare provider.

Q: Is it possible for Targus to interact with herbal teas or natural remedies?

A: Yes, official patient resources explicitly warn that the medicine may interact with certain supplements, herbs, and natural remedies, such as ginger, ginkgo, and garlic. This is due to the potential for synergistic effects that could increase certain risks.

Q: Does Targus affect the results of common blood tests?

A: Yes, regulatory warnings indicate that Targus may affect the results of certain common blood tests. It is known to potentially cause changes such as anemia (low red blood cell count) and hyperkalemia (high potassium levels). These changes are why regular blood monitoring may be required.

How should Targus be stored and disposed of?

How to Store and Dispose of Targus (Flurbiprofen Tablets)

Official regulatory documentation specifies mandatory conditions for storing and disposing of Targus (Flurbiprofen) to maintain product stability and ensure public safety.

Storage Requirements

Targus must be stored at room temperature, typically defined as 15 C to 25 C (59 F to 77 F), and must be kept from freezing.

Condition Requirement
Protection Keep away from heat, moisture, and direct light
Container Store in the closed, original container
Safety Must be kept out of the reach and sight of children

Disposal Instructions

Expired or unused Targus must be disposed of in accordance with local and national pharmaceutical waste regulations. The medicine must not be flushed down the toilet or poured into a drain unless specifically authorized by official guidance, establishing strict environmental protection requirements for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Targus found in:

A-Z Index: